<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18919" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hypertrophic Cardiomyopathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Basit</surname>
            <given-names>Hajira</given-names>
          </name>
          <aff>Brookdale University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Alahmadi</surname>
            <given-names>Mohamed H.</given-names>
          </name>
          <aff>University of Health Sciences, Lahore</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rout</surname>
            <given-names>Preeti</given-names>
          </name>
          <aff>Wilson Case Western University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Saurabh</given-names>
          </name>
          <aff>Guthrie Robert Packer Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hajira Basit declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohamed Alahmadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Rout declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Saurabh Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>6</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18919.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hypertrophic cardiomyopathy (HCM) is an autosomal dominant cardiac myocyte disease caused by mutations in sarcomere protein genes encoding for elements of the contractile machinery of the heart. Characteristic cardiac structural changes include increased left ventricular wall thickness causing dynamic left ventricular outflow obstruction, diastolic dysfunction, myocardial ischemia, arrhythmias, autonomic dysfunction, and mitral regurgitation. In the United States, HCM&#x000a0;is the most common identifiable cause of sudden cardiac death in healthy people&#x000a0;aged younger&#x000a0;than 35, including well-trained athletes. About 60% of patients with HCM have a known gene mutation of the sarcomere or sarcomere-related genes, and obtaining a detailed family history is crucial to help in risk stratification for&#x000a0;affected patients. A comprehensive patient history and thorough physical exam can also help identify patients at risk of malignant arrhythmia. Early intervention through pharmacologic means, implantable cardiac-defibrillator placement, and surgical intervention when warranted have greatly improved the survival rates of HCM in the last few decades.</p>
        <p>This course is designed to provide healthcare professionals with comprehensive knowledge and updates on the diagnosis, management, and latest advancements in understanding HCM. The underlying mechanisms and genetic basis of HCM, including the molecular pathways involved in disease progression, are explored, and the diverse clinical presentations and diagnostic modalities of HCM are reviewed. Current therapeutic approaches, emerging treatments, and research are discussed.&#x000a0;This activity highlights the need to enhance interprofessional healthcare team communication and collaboration through several key mechanisms.&#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the clinical manifestations and risk factors associated with hypertrophic cardiomyopathy including family history, physical exam findings, and diagnostic test results.</p></list-item><list-item><p>Select appropriate screening tools and protocols to identify individuals at risk for hypertrophic cardiomyopathy, including genetic testing for sarcomere gene mutations and echocardiography for structural abnormalities.</p></list-item><list-item><p>Implement evidence-based management strategies for patients diagnosed with hypertrophic cardiomyopathy, including pharmacologic interventions, implantable cardioverter-defibrillator placement, and surgical options when indicated.</p></list-item><list-item><p>Communicate with patients and their families about the diagnosis, prognosis, and treatment options for hypertrophic cardiomyopathy to ensure understanding and shared decision-making.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18919&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18919">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18919.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hypertrophic cardiomyopathy (HCM) is an autosomal dominant cardiac myocyte disease caused by mutations in sarcomere and sarcomere-related protein genes encoding for elements of the contractile machinery of the heart. Characteristic cardiac structural changes include increased left ventricular wall thickness (hypertrophy) causing dynamic left ventricular outflow obstruction, diastolic dysfunction, myocardial ischemia, arrhythmias, autonomic dysfunction, and mitral regurgitation. HCM is a condition that has historically&#x000a0;been referred&#x000a0;to as idiopathic hypertrophic subaortic stenosis.&#x000a0;In the United States, HCM&#x000a0;is the most common identifiable cause of sudden cardiac death in healthy people aged younger than 35, including well-trained athletes.<xref ref-type="bibr" rid="article-18919.r1">[1]</xref></p>
        <p>About 60% of patients with HCM have a known gene mutation of the sarcomere or sarcomere-related genes, and obtaining a detailed family history is crucial to help risk-stratify affected patients.&#x000a0;A comprehensive patient history and thorough physical exam can also help identify patients at risk of malignant arrhythmia. These structural and functional abnormalities can produce fatigue, dyspnea, chest pain, palpitations, and syncope.<xref ref-type="bibr" rid="article-18919.r2">[2]</xref><xref ref-type="bibr" rid="article-18919.r3">[3]</xref><xref ref-type="bibr" rid="article-18919.r4">[4]</xref>&#x000a0;Early intervention through pharmacologic means, internal cardiac defibrillator placement, and surgery, when warranted, have greatly improved the survival rates of HCM in the last few decades.</p>
      </sec>
      <sec id="article-18919.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Familial&#x000a0;HCM occurs as an autosomal dominant Mendelian-inherited disorder in approximately 60% of cases. Incomplete penetrance and variable expression can cause unpredictable manifestations, even within the same family.&#x000a0;In individuals diagnosed with HCM and a known pathogenic sarcomeric gene variant, the&#x000a0;2&#x000a0;most frequently detected genes are &#x003b2;-myosin heavy chain 7 (<italic toggle="yes">MYH7</italic>) and myosin-binding protein C3&#x000a0;<italic toggle="yes">(MYBPC3</italic>), accounting for about 75% of known variant-positive patients.<xref ref-type="bibr" rid="article-18919.r5">[5]</xref>&#x000a0;Less common genetic variants encode thin filament proteins, such as troponin T, troponin I, myosin light chains, and actin;&#x000a0;<italic toggle="yes">TNNI3, TNNT2, TPM1, MYL2, MYL3,</italic>&#x000a0;and<italic toggle="yes">&#x000a0;ACTC1</italic>&#x000a0;mutations make up a smaller proportion of patients, ranging from 1% to 5%. Over 1500 variants causing HCM have been identified, with&#x000a0;most&#x000a0;unique to each family. No clear connection has&#x000a0;been shown&#x000a0;between prognosis and specific gene mutation.</p>
        <p>A significant portion of individuals diagnosed with HCM do not have a genetic explanation for their condition; this includes a subset of patients, up to 40% in some studies, who do not have any family members affected by the disease&#x02014;known as &#x0201c;nonfamilial&#x0201d; HCM. These findings suggest the existence of other yet undiscovered pathophysiological mechanisms that may play a role in the manifestation of HCM pathology.<xref ref-type="bibr" rid="article-18919.r6">[6]</xref>&#x000a0;Recent data has also associated&#x000a0;abnormal myocardial calcium kinetics with the cause of inappropriate myocardial hypertrophy and specific features of HCM, especially in patients with diastolic functional abnormalities.<xref ref-type="bibr" rid="article-18919.r7">[7]</xref><xref ref-type="bibr" rid="article-18919.r8">[8]</xref><xref ref-type="bibr" rid="article-18919.r9">[9]</xref><xref ref-type="bibr" rid="article-18919.r10">[10]</xref></p>
      </sec>
      <sec id="article-18919.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The prevalence of HCM in the general population worldwide is 0.2% (1 in 500 adults), as determined by echocardiographic studies. Morphologic abnormalities are found in approximately 25% of first-degree relatives of patients with HCM. HCM is more common in males than females,&#x000a0;although the condition is autosomal dominant, and genetic inheritance does not follow sex predilection. The explanation for this phenomenon may be related to&#x000a0;screening strategies, genetics, or hormonal regulation.<xref ref-type="bibr" rid="article-18919.r11">[11]</xref>&#x000a0;However, there is evidence that women are diagnosed at an older age and have a worse prognosis, suggesting that diagnosis strategies should be revisited.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopupWithQuestions/165854#link_30747730">[2]</ext-link><xref ref-type="bibr" rid="article-18919.r5">[5]</xref>&#x000a0;The most common presentation of HCM is in the third decade of life but may be present at any age, from newborns to older individuals.</p>
      </sec>
      <sec id="article-18919.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Wall thickening can involve any area of the myocardium, but the interventricular septal wall is the most commonly affected location. In the absence of other conditions that could&#x000a0;possibly&#x000a0;contribute to left ventricular hypertrophy (LVH), such as severe hypertension or aortic stenosis, HCM&#x000a0;is usually diagnosed&#x000a0;by echocardiogram.</p>
        <list list-type="bullet">
          <list-item>
            <p>HCM in adults&#x000a0;is characterized&#x000a0;by a left ventricular wall thickness of 15 mm or more, with a septal/posterior wall thickness ratio of over 1.3 in&#x000a0;patients who are normotensive&#x000a0;or over 1.5 in those who are hypertensive. A wall thickness of 13 to 14 mm can be diagnostic for positive family history, evidence of&#x000a0;left ventricular outflow tract obstruction (LVOTO), or electrocardiogram (ECG) abnormalities.<xref ref-type="bibr" rid="article-18919.r12">[12]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In children, hypertrophy&#x000a0;is defined&#x000a0;as a wall thickness that is at least&#x000a0;2&#x000a0;standard deviations above the mean (z-score &#x02265;2) for age, sex, or body size or LV wall thickness of 13 mm or more.<xref ref-type="bibr" rid="article-18919.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>Five mechanisms contribute to the development of HCM: dynamic LVOTO, mitral regurgitation, diastolic dysfunction, myocardial ischemia, and autonomic dysfunction.</p>
        <p><bold>Dynamic LVOTO:</bold>&#x000a0;Obstruction can occur either at rest or with exercise. About one-third of patients will each have no obstruction, obstruction with exercise, or obstruction at rest. A gradient of 30 mm Hg or more is considered hemodynamically significant and is associated with death and progression to heart failure; however, a gradient of 50 mm Hg or more is regarded as a threshold for surgical and percutaneous intervention, primarily if symptomatic.<xref ref-type="bibr" rid="article-18919.r5">[5]</xref>&#x000a0;The gradient can also be provoked by changes in preload and afterload, as later described in the History and Physical section.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>The likelihood of obstruction is typically determined by the pattern of hypertrophy in the left ventricle, with classical asymmetric left ventricular hypertrophy (LVH) most commonly affecting the basal interventricular septum.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>LVOTO&#x000a0;in HCM can&#x000a0;be attributed&#x000a0;to&#x000a0;2 main causes. The first is an increase in septal thickness, which narrows the LVOT and leads to abnormal movement of the mitral valve leaflets. Systolic anterior motion (SAM) of the mitral valve is common in HCM&#x000a0;and&#x000a0;is&#x000a0;defined&#x000a0;as displacement of the distal anterior mitral valve leaflet into the LVOT.<xref ref-type="bibr" rid="article-18919.r13">[13]</xref>&#x000a0;The second cause is alterations in the structure of the mitral valve, such as elongated leaflets and displacement of the papillary muscles and valve apparatus towards the anterior region. These structural changes render the valve liable to unnatural flow vectors. SAM is more common with a hyperdynamic left ventricle; the ejection fraction is often elevated in HCM (&#x0003e;65%).<xref ref-type="bibr" rid="article-18919.r14">[14]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Mitral Regurgitation:&#x000a0;</bold>This&#x000a0;can be due to LVOTO or SAM of the mitral valve. The regurgitant jet direction can guide the causative mechanism, and SAM is usually directed posteriorly.<xref ref-type="bibr" rid="article-18919.r5">[5]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p><bold>Diastolic Dysfunction:&#x000a0;</bold>The presence of&#x000a0;LVH in conjunction with myocardial disarray and fibrosis increases left ventricular stiffness.&#x000a0;This, in turn, negatively affects myocardial relaxation and diastolic function, ultimately leading to increased intracavitary pressures in both the left ventricle (LV) and left atrium (LA).&#x000a0;Delayed inactivation from abnormal intracellular calcium reuptake has also&#x000a0;been observed&#x000a0;in patients with HCM.</p>
        <p><bold>Myocardial Ischemia:&#x000a0;</bold>Common findings in HCM include myocardial hypertrophy, microvascular dysfunction, impaired coronary flow reserve, and medial and intimal hypertrophy of intramural arterioles. All these factors contribute&#x000a0;to a mismatch between myocardial oxygen supply and demand, resulting in myocardial fibrosis.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p><bold>Autonomic Dysfunction:&#x000a0;</bold>Autonomic dysfunction in HCM&#x000a0;is defined&#x000a0;as an abnormal blood pressure response to exercise&#x02014;specifically, a failure to increase systolic blood pressure by at least 20 mm Hg or a drop in systolic blood pressure during exercise of more than 20 mm Hg from the peak value&#x02014;is associated with poor prognosis. The proposed mechanism involves the inappropriate firing of stretch-sensitive mechanoreceptors in the LV myocardium, resulting in unreciprocated changes in systemic vascular resistance, which may lead to episodes of presyncope or syncope.</p>
        <p>The most common arrhythmia in HCM is atrial fibrillation, present in about 25% of patients, which is 4- to 6-fold higher than in the general population. Atrial fibrillation&#x000a0;is poorly tolerated&#x000a0;in patients with HCM. Due to decreased LV compliance, up to 35% of left ventricular filling&#x000a0;depends&#x000a0;on left atrial contraction.&#x000a0;The decreased LV filling can lead to lower cardiac output and hypotension.<xref ref-type="bibr" rid="article-18919.r7">[7]</xref>&#x000a0;Non-sustained ventricular tachycardia (NSVT) is present in 20% to 30% of patients with HCM. NSVT can lead to ventricular fibrillation&#x02014;the most common cause of sudden cardiac death (SCD). Potential etiology of the arrhythmias includes interstitial fibrosis, myocyte disarray, and myocardial ischemia.<xref ref-type="bibr" rid="article-18919.r14">[14]</xref></p>
      </sec>
      <sec id="article-18919.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The histology of HCM provides crucial insights into the structural changes occurring within the myocardium.&#x000a0;HCM&#x000a0;is characterized&#x000a0;by enlarged cardiomyocytes in the heart muscle, which have eosinophilic cytoplasm and box-shaped nuclei. These cells can exhibit unusual shapes, such as Y-shaped branches, frequent side-to-side connections, or a spiraled appearance around a central fibrous core. The resulting disorganized architecture of the heart muscle can lead to myocardial disarray, with bundles of cardiomyocytes arranged at different angles to each other.</p>
        <p>The affected areas can be adjacent to areas of normal myocardium in a patchy nature. The disarray&#x000a0;is inversely correlated&#x000a0;to fibrosis. Fibrosis is seen interstitially and will stain blue with the Masson trichrome stain.<xref ref-type="bibr" rid="article-18919.r5">[5]</xref><xref ref-type="bibr" rid="article-18919.r14">[14]</xref>&#x000a0;Microvascular ischemia can cause cell death and replacement fibrosis, while interstitial fibrosis can lead to arrhythmogenic foci.&#x000a0;HCM is also associated with intercellular junction abnormalities in the intercalated discs and desmosomes, which can form &#x0201c;huge mega-discs&#x0201d; that likely&#x000a0;contribute&#x000a0;to diastolic dysfunction and arrhythmias.<xref ref-type="bibr" rid="article-18919.r5">[5]</xref></p>
      </sec>
      <sec id="article-18919.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Up to 50% of individuals diagnosed with HCM may not experience any symptoms or may only have mild symptoms&#x02014;especially patients without LVOTO.<xref ref-type="bibr" rid="article-18919.r12">[12]</xref>&#x000a0;The patient history should focus on both family and personal history:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Family history of HCM, sudden cardiac death, unexplained syncope&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Personal history of chest pain, syncope, unexplained dizziness, palpitations, shortness of breath, chest pain</p>
          </list-item>
        </list>
        <p>Shortness of breath and chest discomfort are often caused by underlying diastolic dysfunction and LVOTO. Chest pain can present as typical or atypical angina. Individuals with LVOTO may experience more severe symptoms after consuming a heavy meal (postprandial exacerbation). Dizziness and syncope can occur at rest or during physical exertion, and arrhythmia or dynamic LVOTO can be the underlying causes. Palpitations are also common and may indicate underlying episodes of atrial fibrillation or ventricular arrhythmia. Sudden cardiac death represents the most devastating presenting symptom.</p>
        <p>Physical examination findings&#x000a0;are characterized&#x000a0;by a&#x000a0;&#x0201c;jerky&#x0201d; pulse&#x000a0;with rapid upstroke and downstroke, a&#x000a0;normal&#x000a0;S1 and split S2, an S3 due to decompensated heart failure, prominent &#x0201c;a wave&#x0201d; of jugular venous pressure, laterally displaced apical impulse, and double carotid pulse. An S4 is also&#x000a0;common&#x000a0;with LVH.</p>
        <p>A harsh mid-systolic ejection murmur at the left sternal border is affected as follows:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Diminished intensity with increased preload (squatting) or afterload (handgrip)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Increased intensity with a decrease in preload (Valsalva maneuver, standing) or with any reduction in afterload (vasodilator administration)</p>
          </list-item>
        </list>
        <p>Exercise will also increase the murmur. If mitral regurgitation is present, a holosystolic, blowing murmur may be loudest at the apex.</p>
      </sec>
      <sec id="article-18919.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Individuals with a family history of HCM, cardiac symptoms or a cardiac event, a heart murmur revealed during a routine physical examination, or an abnormal 12-lead ECG may require further clinical assessment. To accurately evaluate for HCM, a comprehensive cardiac history, including family history spanning&#x000a0;3&#x000a0;generations, and an extensive physical examination (incorporating special provocative maneuvers such as Valsalva, squat-to-stand, or passive leg raising) are necessary. An ECG and cardiac imaging to identify&#x000a0;LVH should&#x000a0;be performed&#x000a0;in all patients.<xref ref-type="bibr" rid="article-18919.r15">[15]</xref><xref ref-type="bibr" rid="article-18919.r16">[16]</xref><xref ref-type="bibr" rid="article-18919.r17">[17]</xref></p>
        <p><bold>Laboratory testing:&#x000a0;</bold>Lab testing, including Troponin I and T, can&#x000a0;be used to&#x000a0;detect suspected ischemic events.&#x000a0;Elevation of the natriuretic peptides, especially those of the brain, can also be used as a marker of heart failure. Elevated NT-pro-BNP levels&#x000a0;are correlated&#x000a0;with LV wall stress and diastolic and systolic dysfunction.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <p><bold>Electrocardiogram:</bold>&#x000a0;ECG is often abnormal, even if LVOTO is not present. Findings include localized or widespread repolarization changes, prominent&#x000a0;Q-waves in the inferior (II, III, and aVF) and lateral&#x000a0;(I, aVL, and V4-V6) leads, left atrial or biatrial enlargement, left axis deviation, and deeply inverted T-waves. Prominent Q-waves can represent thickened interventricular septal depolarization.<xref ref-type="bibr" rid="article-18919.r14">[14]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <p><bold>Transthoracic echocardiogram:</bold>&#x000a0;This echocardiogram can demonstrate the typical cardiac morphology of unexplained LVH with a wall thickness of more than 15 mm. About one-third of patients with HCM will also have increased RV wall thickness (&#x0003e;8 mm). As noted above,&#x000a0;a septal/posterior wall thickness ratio over 1.3 in normotensive patients or over 1.5 in hypertensive patients is also diagnostic of HCM. Transthoracic echocardiogram (TTE) can also show systolic and diastolic function, the presence and severity of any LVOT gradient, and the degree of mitral regurgitation or SAM (of note, SAM has a specificity of 99% for HCM). Left atrial measurements and pulmonary artery pressures should also be imaged. TTE with contrast can also be performed in patients unable to have a cardiac magnetic resonance imaging scan, such as if an&#x000a0;implantable cardioverter-defibrillator (ICD) is present (see&#x000a0;<bold>Image.</bold>&#x000a0;Hypertrophic Cardiomyopathy, Echocardiogram).&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <p><bold>Ambulatory ECG monitoring (Holter):</bold>&#x000a0;Monitoring should be performed for 24 to 48 hours in all patients diagnosed with HCM for risk assessment of ventricular arrhythmias and sudden death.</p>
        <p><bold>Exercise stress testing:</bold>&#x000a0;This can be performed for risk stratification and LVOT gradient assessment. Exercise stress testing with TTE is the preferred method to image the LVOT because this simulates physiologic stress.<xref ref-type="bibr" rid="article-18919.r18">[18]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <p><bold>Cardiac magnetic resonance:</bold>&#x000a0;The cardiac magnetic resonance (CMR) is becoming more commonly used to characterize cardiac tissue and structure in patients with HCM and their relatives. With gadolinium, CMR can also detect myocardial fibrosis, an important prognostic indicator. Late gadolinium enhancement (LGE) is present in over 60% of patients with symptomatic HCM and is thought to be a marker for replacement fibrosis.<xref ref-type="bibr" rid="article-18919.r5">[5]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>The American Heart Association&#x02019;s (AHA) guidelines suggest using CMR in the following situations:
<list list-type="bullet"><list-item><p>For patients in whom TTE is inconclusive, or images are&#x000a0;suboptimal</p></list-item><list-item><p>For patients diagnosed with LVH who may have alternative diagnoses, such as Fabry disease, amyloidosis, or athlete&#x02019;s heart</p></list-item><list-item><p>For patients with unclear benefits regarding ICD placement</p></list-item><list-item><p>TTE can miss patients with the uncommon apical or anterolateral wall hypertrophy forms of HCM, so CMR is preferred for imaging this variant.</p></list-item><list-item><p>To image more subtle structural findings such as myocardial crypts, elongated mitral leaflets, and expanded extracellular space&#x000a0;<xref ref-type="bibr" rid="article-18919.r12">[12]</xref></p></list-item><list-item><p>To define the LVOT when planning invasive intraseptal reduction treatments&#x000a0;<xref ref-type="bibr" rid="article-18919.r19">[19]</xref><xref ref-type="bibr" rid="article-18919.r20">[20]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Some patients may also require additional studies as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Cardiac catheterization:</bold>&#x000a0;This catheterization can help characterize cardiac hemodynamics, the degree of left ventricular outflow obstruction, and the coronary vessel anatomy.</p>
          </list-item>
          <list-item>
            <p><bold>Electrophysiological studies:&#x000a0;</bold>These studies can help determine the origin of the arrhythmias.</p>
          </list-item>
        </list>
        <p>
<bold>Risk Stratification in Young Athletes and Patients</bold>
</p>
        <p>HCM is a leading cause of sudden cardiac death (SCD) in athletes younger than 35 years (along with&#x000a0;congenital anomalies of the coronary arteries and arrhythmogenic right ventricular cardiomyopathy [ARVC]). For most patients with HCM, engaging in mild-to-moderate-intensity recreational exercise can be beneficial. Special attention is paid to athletes because about 25% of SCD cases occur during physical activity, such as sports.<xref ref-type="bibr" rid="article-18919.r21">[21]</xref>&#x000a0;Risk stratification for young athletes to evaluate for HCM is performed using ECG and echocardiography. However, these testing modalities have low sensitivity, so CMR has been suggested as a test for all young athletes with a personal history of syncope, a family history of syncope or SCD, or an abnormal or indeterminate echocardiogram.<xref ref-type="bibr" rid="article-18919.r8">[8]</xref>&#x000a0;For athletes older than 35 years, coronary artery disease is the most common cause of SCD.</p>
        <p>In the United States, HCM and an anomalous origin of coronary arteries are the most common causes of SCD in all patients younger than 35, while in Europe, arrhythmogenic cardiomyopathies (including ARVC) and channelopathies are more common.<xref ref-type="bibr" rid="article-18919.r22">[22]</xref><xref ref-type="bibr" rid="article-18919.r23">[23]</xref>&#x000a0;Current guidelines recommend against competitive sports and strenuous exercise, given the association of&#x000a0;SCD in young athletes with HCM.<xref ref-type="bibr" rid="article-18919.r12">[12]</xref>&#x000a0;However, the prospective, observational LIVE-HCM trial studying the effect of vigorous exercise did not find an association with life-threatening arrhythmia or death. Results from this study found that most significant cardiac events occurred during activities of daily living.<xref ref-type="bibr" rid="article-18919.r24">[24]</xref>&#x000a0;Another ongoing trial at Yale University (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02549664">NCT02549664</ext-link>) is also studying the effect of exercise on patients with HCM. As no well-designed trials have definitively proven that avoiding strenuous exercise helps decrease the chances of SCD, some experts recommend shared decision-making between patients and physicians after fully explaining all possible risks and benefits.<xref ref-type="bibr" rid="article-18919.r21">[21]</xref><xref ref-type="bibr" rid="article-18919.r22">[22]</xref></p>
      </sec>
      <sec id="article-18919.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment strategies for HCM are based on observational data and clinical experience since no large randomized trials have&#x000a0;been performed. Pharmacological therapy is the first-line approach to symptomatic HCM. Initial recommended medications include&#x000a0;negative&#x000a0;inotropic agents, including beta blockers,&#x000a0;nondihydropyridine&#x000a0;calcium channel blockers, and disopyramide.<xref ref-type="bibr" rid="article-18919.r25">[25]</xref><xref ref-type="bibr" rid="article-18919.r26">[26]</xref></p>
        <p>
<bold>Medical Intervention</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Mavacamten</bold>&#x000a0;is a first-in-class drug approved in 2022 by the Food and Drug Administration that is specifically for the treatment of obstructive HCM. This medicine is the first selective, allosteric, reversible small-molecule adenosine triphosphatase inhibitor of cardiac myosin that&#x000a0;functions by blocking the interaction between myosin and actin within cardiac muscle cells, which exerts a negative inotropic effect. This mechanism helps to relieve the obstruction in the left ventricular outflow tract, thereby enhancing blood flow and alleviating symptoms.&#x000a0;Mavacamten is presently indicated for the treatment of adults with symptomatic heart failure (New York Heart Association [NYHA] class II and III) due to obstructive HCM.&#x000a0;Typical side effects include dizziness, fainting, and shortness of breath. Severe side effects may involve heart failure that requires close monitoring and possible dosage adjustment if the left ventricular ejection fraction drops below 50%.</p>
          </list-item>
          <list-item>
            <p><bold>Beta-blockers</bold>&#x000a0;are the first line of management for most HCM cases. Patients should&#x000a0;be titrated&#x000a0;to a therapeutic dose that provides symptom relief. Beta-blockade failure should not&#x000a0;be declared&#x000a0;until suppression of the resting heart rate&#x000a0;is demonstrated. This approach ensures that patients receive optimal treatment benefits while minimizing the risk of adverse effects.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Calcium channel blockers</bold>, such as&#x000a0;diltiazem and verapamil, are known to alleviate symptoms in patients with obstructive HCM. These drugs can have vasodilating properties, but they can also have&#x000a0;negative&#x000a0;inotropic and negative chronotropic effects, which may limit their use. Evidence does not support using calcium channel blockers in combination with beta-blockers as a therapy for HCM.&#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Disopyramide</bold>&#x000a0;is&#x000a0;a sodium channel blocker classified as a class Ib antiarrhythmic drug; this is also a potent&#x000a0;negative&#x000a0;inotropic agent that is used off-label for the treatment of HCM. Disopyramide helps reduce outflow obstruction and associated symptoms. As cytochrome P450 3A4 metabolizes this drug, many drugs, such as calcium channel blockers, can interact with disopyramide and affect its serum levels.&#x000a0;Due to the anticholinergic properties of disopyramide, it can potentially cause urinary retention and exacerbate related conditions like glaucoma and myasthenia gravis.</p>
          </list-item>
          <list-item>
            <p><bold>Diuretics</bold>&#x000a0;can be given carefully in patients without LVOT obstruction who have refractory heart failure symptoms presenting with volume overload.&#x000a0;Volume depletion decreases stroke volume and worsens the LVOT gradient.&#x000a0;This&#x000a0;can lead to hypotension, lightheadedness, and syncope.</p>
          </list-item>
          <list-item>
            <p>Certain medications should be avoided or used very cautiously as they can worsen symptoms. These include vasodilators, amlodipine, nifedipine, nitroglycerin, angiotensin-converting enzyme/angiotensin II receptor blockers, and adrenergic receptor &#x003b2;-agonists like dopamine and dobutamine.<xref ref-type="bibr" rid="article-18919.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>Patients with nonobstructed HCM are usually treated medically.<xref ref-type="bibr" rid="article-18919.r18">[18]</xref><xref ref-type="bibr" rid="article-18919.r28">[28]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Implantable Cardiac-Defibrillator Placement</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The placement of an implantable&#x000a0;cardiac-defibrillator&#x000a0;(ICD) is&#x000a0;considered&#x000a0;largely&#x000a0;responsible for the improved mortality of HCM over the last 20 years.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Any patient with risk factors for sudden cardiac death should&#x000a0;be considered&#x000a0;for ICD. Risk factors include the following: recent unexplained syncope, HCM-related SCD in a close relative, thin-walled akinetic or dyskinetic LV apical aneurysm with scarring, frequent or prolonged episodes of ventricular tachycardia on ambulatory monitoring, extensive late gadolinium enhancement on CMR, and massive LVH (&#x0003e;30 mm).&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Multiple study results have shown&#x000a0;primary&#x000a0;ICD placement terminates 3% to 4% of malignant tachyarrhythmias per year, and that number rises to 10% for secondary ICD placement (after cardiac arrest).<xref ref-type="bibr" rid="article-18919.r27">[27]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Although overall beneficial, the complication rate can be up to 10% per year, including lead fractures and infections.<xref ref-type="bibr" rid="article-18919.r27">[27]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Guidelines for ICD placement in children are less clear as children have less marginal benefit and increased complications from ICDs than adults due to smaller size.<xref ref-type="bibr" rid="article-18919.r21">[21]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Surgical intervention</bold>
</p>
        <p>Up to 50% of patients with HCM may be refractory to medical treatment.<xref ref-type="bibr" rid="article-18919.r29">[29]</xref>&#x000a0;Indications for surgical intervention include New York Heart Association III/IV class symptoms despite optimal medical therapy, syncope related to hemodynamic compromise from LVOT obstruction, or an LVOT gradient of more than 50 mm Hg.</p>
        <list list-type="bullet">
          <list-item>
            <p>Septal reduction therapy&#x000a0;includes left ventricular septal myectomy, which immediately reduces the outflow tract obstruction. Mitral valve repair or remodeling is sometimes also performed to reduce mitral regurgitation or&#x000a0;further&#x000a0;relieve LVOTO. Complete heart block requiring a permanent pacemaker is a myectomy complication occurring 1% to 5% of the time. Mortality is low with experienced surgeons.<xref ref-type="bibr" rid="article-18919.r27">[27]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Alcohol septal ablation can also be performed for the same indications and has the added benefit of faster recovery time. However, the LVOT obstruction often takes up to 3 months to show improvement, and results are less uniform than&#x000a0;with&#x000a0;surgical myectomy. In addition, the risk of complete heart block is higher (10% to 15%), and a post-ablation scar can form, causing an arrhythmogenic focus.<xref ref-type="bibr" rid="article-18919.r30">[30]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Given that atrial fibrillation is the most common arrhythmia associated with HCM, a Maze procedure is often done in conjunction if a myectomy is required, and it is often successful in decreasing or resolving this arrhythmia.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Radiofrequency ablation&#x000a0;is a newer technique&#x000a0;being studied&#x000a0;for left ventricular septal reduction. Results are similarly effective to the more established surgical myectomy and alcohol ablation techniques. The most common adverse effect is pericardial effusion requiring drainage. Further studies of this technique are needed.<xref ref-type="bibr" rid="article-18919.r29">[29]</xref><xref ref-type="bibr" rid="article-18919.r31">[31]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>A heart transplant&#x000a0;is recommended&#x000a0;as a last resort in patients who have failed all medical and surgical treatments (see&#x000a0;<bold>Image.</bold>&#x000a0;Hypertrophic Cardiomyopathy&#x000a0;Treatment Mapping).<xref ref-type="bibr" rid="article-18919.r27">[27]</xref><xref ref-type="bibr" rid="article-18919.r32">[32]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18919.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>For a correct diagnosis of HCM to&#x000a0;be made, other&#x000a0;diagnoses must&#x000a0;be excluded first, including the following:</p>
        <p><bold>Fabry disease:</bold>&#x000a0;This disease is transmitted through X-linked inheritance and is caused by an &#x003b1;-galactosidase deficiency characterized by angiokeratomas and peripheral neuropathies.</p>
        <p><bold>LEOPARD syndrome:</bold>&#x000a0;Patients with this syndrome exhibit multiple lentigines.</p>
        <p><bold>Amyloidosis:</bold>&#x000a0;Patients with ventricular hypertrophy due to amyloidosis will most likely have bilateral carpal tunnel syndrome, nephrotic syndrome, or skin abnormalities. The ECG may show an arteriovenous block, and the echocardiogram may show a &#x0201c;sparkling&#x0201d; appearance.</p>
        <p><bold>Danon disease:</bold>&#x000a0;This is an X-linked&#x000a0;lysosomal glycogen-storage disease with the clinical triad of skeletal myopathy,&#x000a0;cardiomyopathy, and intellectual disability.</p>
        <p><bold>Friedrich ataxia:</bold>&#x000a0;This&#x000a0;is the most common cause of inherited ataxia caused by a mutation in the frataxin gene, a mitochondrial protein found in neurons and cardiomyocytes.&#x000a0;Ataxia, dysarthria, and other cerebellar signs usually become prominent during childhood.&#x000a0;</p>
        <p><bold>Aortic stenosis or insufficiency/pulmonary hypertension:</bold>&#x000a0;These clinical entities combine LVH with aortic valve or pulmonary artery changes and can cause&#x000a0;symmetric or asymmetric LVH, similar to HCM. Abnormalities may be detectable on echocardiogram.&#x000a0; &#x000a0;</p>
        <p><bold>Athlete&#x02019;s&#x000a0;heart:</bold>&#x000a0;A history of athletic achievement and strenuous&#x000a0;training should help in differential diagnosis. An echocardiogram may show a low-normal ejection fraction, and all the heart chambers may be enlarged instead of just the LV. Contractility reserve&#x000a0;is increased, but this may not be apparent on echocardiography.&#x000a0;CMR is a valuable tool to differentiate this from HCM, as&#x000a0;athlete&#x02019;s&#x000a0;heart will not show LGE (late gadolinium enhancement).<xref ref-type="bibr" rid="article-18919.r33">[33]</xref><xref ref-type="bibr" rid="article-18919.r34">[34]</xref></p>
        <p><bold>Hypertensive heart disease:</bold>&#x000a0;Diffuse atherosclerotic changes and a history of essential hypertension should suggest the diagnosis. HCM is also associated with systolic anterior motion, late gadolinium enhancement, and preferential involvement of the apical, anterolateral free wall or posterior septum, which is usually not seen in hypertensive heart disease.</p>
      </sec>
      <sec id="article-18919.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Understanding the prognosis of HCM is essential for guiding patient care and counseling. Factors such as age of onset, genetic mutations, degree of hypertrophy, presence of symptoms, and complications significantly influence the long-term outlook. A nuanced understanding of these prognostic indicators is crucial for clinicians to tailor treatment strategies and optimize patient outcomes.</p>
        <list list-type="bullet">
          <list-item>
            <p>Previously, mortality rates of 1% to 4% were reported in patients with HCM. With appropriate treatment, these numbers are now thought to be closer to 0.5%.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Even though many patients with HCM are asymptomatic, the first clinical presentation may be sudden death from malignant arrhythmias.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Increased left atrial size (transverse linear dimension &#x0003e;48 mm or volume &#x0003e;118 mL)&#x000a0;is correlated&#x000a0;with an increased risk of death, heart failure, and atrial fibrillation.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopupWithQuestions/165854#link_31234582">[5]</ext-link></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18919.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of HCM pose significant challenges in case management and prognostication.&#x000a0;Understanding the diverse array of complications associated with HCM is essential for clinicians to implement appropriate preventive measures and therapeutic interventions, ultimately improving patient outcomes and quality of life.</p>
        <p>These complications encompass a spectrum of cardiovascular events, including the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Ventricular arrhythmias</p>
          </list-item>
          <list-item>
            <p>Congestive heart failure</p>
          </list-item>
          <list-item>
            <p>Infective endocarditis of the mitral valve</p>
          </list-item>
          <list-item>
            <p>Atrial fibrillation</p>
          </list-item>
          <list-item>
            <p>Embolic phenomenon</p>
          </list-item>
          <list-item>
            <p>Sudden death</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18919.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Preventing and deterring the progression of HCM is paramount in reducing its associated morbidity and mortality. Lifestyle modifications and targeted interventions can be crucial&#x000a0;in mitigating its impact. Understanding the strategies for deterrence and prevention is vital for healthcare professionals to empower patients with HCM and optimize their long-term cardiac health.&#x000a0;Patients should be screened and advised on preventing and treating comorbidities that can exacerbate the severity of HCM. These comorbidities include atherosclerotic cardiovascular disease, obesity, hypertension, and sleep apnea.&#x000a0;&#x000a0;</p>
        <p>Individuals with a history of sudden death in a family member within&#x000a0;3&#x000a0;generations should&#x000a0;be screened&#x000a0;for the disorder. Unless symptomatic, screening by ECG, echocardiography, or CMR usually begins at 12 years and continues yearly until age 21, after which screening can occur every 3 to 5 years. Genetic testing can&#x000a0;be performed&#x000a0;if a gene causing HCM can&#x000a0;be identified&#x000a0;in a proband, but this is not the preferred strategy per the Journal of the American College of Cardiology due to variable genetic penetrance and expression, as well as the absence of identifiable genetic mutations in up to 40% of HCM cases.<xref ref-type="bibr" rid="article-18919.r12">[12]</xref>&#x000a0;Individuals with abnormal blood pressure in response to exercise should also&#x000a0;be screened.&#x000a0;Significant controversy exists about the safety of participating in organized or competitive sports in patients with HCM. Associated risks, particularly sudden cardiac death, should be discussed in depth with affected patients and caregivers.</p>
      </sec>
      <sec id="article-18919.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Additional pertinent information includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Early diagnosis of HCM is important as it allows the healthcare professional to prescribe&#x000a0;appropriate treatment.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>If a patient is diagnosed with HCM, close family members should be screened.</p>
          </list-item>
          <list-item>
            <p>Mutations in &#x003b2;-myosin heavy chain 7 (<italic toggle="yes">MYH7</italic>) and myosin-binding protein C3 (<italic toggle="yes">MYBPC3</italic>) account for about 75% of known variant-positive patients.</p>
          </list-item>
          <list-item>
            <p>Systolic anterior motion is highly suggestive of HCM and is associated with mitral regurgitation.</p>
          </list-item>
          <list-item>
            <p>Those who have concomitant mitral regulation and diastolic dysfunction are also prone to recurrent episodes of heart failure.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Atrial fibrillation is the most common arrhythmia associated with HCM.</p>
          </list-item>
          <list-item>
            <p>Ventricular tachycardia degenerating into ventricular fibrillation is the most common cause of SCD.</p>
          </list-item>
          <list-item>
            <p>The most common identifiable cause of SCD in the United States is HCM. In Europe, the most common cause is arrhythmogenic right ventricular cardiomyopathy.</p>
          </list-item>
          <list-item>
            <p>Screening and monitoring are usually performed through a combination of ECG, echocardiogram, and CMR.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The increased use of ICDs is thought to be the reason for improved survival in patients with HCM.</p>
          </list-item>
          <list-item>
            <p>Surgical myectomy and alcohol ablation are&#x000a0;2 well-established techniques for reducing the left ventricular septal wall thickness and decreasing LVOTO.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18919.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients with HCM are at high&#x000a0;risk of SCD; therefore, early identification and management of HCM cases are imperative in reducing morbidity and mortality.&#x000a0;The care of patients with HCM necessitates a collaborative approach among healthcare professionals to ensure patient-centered care and improve overall outcomes. Cardiologists, electrophysiologists, primary care physicians, emergency medicine physicians, radiologists, geneticists, advanced practitioners, nurses, pharmacists, and other healthcare professionals involved in the care of these patients should possess the essential clinical skills and knowledge to diagnose and manage HCM accurately.&#x000a0;This&#x000a0;includes expertise in recognizing the varied clinical presentations and understanding the nuances of diagnostic techniques such as ECG, echocardiogram, and CMR. Patient and caregiver education about&#x000a0;disease progression, medication compliance, possible risks and benefits of exercise, and&#x000a0;the importance of&#x000a0;cardiac follow-up is crucial for optimal outcomes.</p>
        <p>A strategic approach involving evidence-based strategies to optimize treatment plans and minimize adverse effects is equally crucial. Ethical considerations must guide decision-making, ensuring informed consent and respecting patient autonomy in treatment choices, especially given the association with&#x000a0;SCD and the unpredictable nature of this disease. Each healthcare professional must&#x000a0;be aware of&#x000a0;their responsibilities and contribute their unique expertise to the patient&#x02019;s care plan, fostering a multidisciplinary approach. Effective interprofessional communication is paramount, allowing seamless information exchange and collaborative decision-making among the team members. Care coordination plays a pivotal role in ensuring that the patient&#x02019;s journey from diagnosis to treatment and follow-up is well-managed, minimizing errors and enhancing patient safety. By embracing these principles of skill, strategy, ethics, responsibilities, interprofessional communication, and care coordination,&#x000a0;the healthcare team can deliver patient-centered care, ultimately improving patient outcomes and enhancing team performance.</p>
      </sec>
      <sec id="article-18919.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18919&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18919">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/hypertrophic-cardiomyopathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=18919">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18919/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18919">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-18919.s17">
        <fig id="article-18919.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Hypertrophic Cardiomyopathy, Echocardiogram. The image illustrates hypertrophic cardiomyopathy, a condition affecting the left ventricle of the heart. Contributed by Y Hafeez, DO</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="q-1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-18919.s18">
        <fig id="article-18919.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Hypertrophic Cardiomyopathy Treatment Mapping. The diagram illustrates treatment mapping adopted from the American Heart Association guidelines, 2020. HCM, hypertrophic cardiomyopathy; NSVT, non-sustained ventricular tachycardia; CRT, cardiac resynchronization therapy, NYHA, New York Heart Association; GDMT, guideline-directed medical therapy; LBBB, left bundle branch block; ICD, Implantable cardioverter defibrillator Contributed by MH Alahmadi, MBBS, MS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="HCM" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-18919.s19">
        <title>References</title>
        <ref id="article-18919.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Czimbalmos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Csecs</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Toth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kiss</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Suhai</surname>
                <given-names>FI</given-names>
              </name>
              <name>
                <surname>Sydo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dohy</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Apor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Merkely</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vago</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The demanding grey zone: Sport indices by cardiac magnetic resonance imaging differentiate hypertrophic cardiomyopathy from athlete's heart.</article-title>
            <source>PLoS One</source>
            <year>2019</year>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>e0211624</fpage>
            <pub-id pub-id-type="pmid">30763323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spudich</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations.</article-title>
            <source>Pflugers Arch</source>
            <year>2019</year>
            <month>May</month>
            <volume>471</volume>
            <issue>5</issue>
            <fpage>701</fpage>
            <page-range>701-717</page-range>
            <pub-id pub-id-type="pmid">30767072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Driel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nijenkamp</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huurman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Michels</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van der Velden</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Sex differences in hypertrophic cardiomyopathy: new insights.</article-title>
            <source>Curr Opin Cardiol</source>
            <year>2019</year>
            <month>May</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>254</fpage>
            <page-range>254-259</page-range>
            <pub-id pub-id-type="pmid">30747730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kraft</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Montag</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Altered force generation and cell-to-cell contractile imbalance in hypertrophic cardiomyopathy.</article-title>
            <source>Pflugers Arch</source>
            <year>2019</year>
            <month>May</month>
            <volume>471</volume>
            <issue>5</issue>
            <fpage>719</fpage>
            <page-range>719-733</page-range>
            <pub-id pub-id-type="pmid">30740621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Popa-Fotea</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Micheu</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Bataila</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Scafa-Udriste</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dorobantu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Scarlatescu</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Zamfir</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stoian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Onciul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dorobantu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Exploring the Continuum of Hypertrophic Cardiomyopathy-From DNA to Clinical Expression.</article-title>
            <source>Medicina (Kaunas)</source>
            <year>2019</year>
            <month>Jun</month>
            <day>23</day>
            <volume>55</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">31234582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wijnker</surname>
                <given-names>PJM</given-names>
              </name>
              <name>
                <surname>Sequeira</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kuster</surname>
                <given-names>DWD</given-names>
              </name>
              <name>
                <surname>Velden</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>Hypertrophic Cardiomyopathy: A Vicious Cycle Triggered by Sarcomere Mutations and Secondary Disease Hits.</article-title>
            <source>Antioxid Redox Signal</source>
            <year>2019</year>
            <month>Aug</month>
            <day>01</day>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>318</fpage>
            <page-range>318-358</page-range>
            <pub-id pub-id-type="pmid">29490477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Philipson</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Rader</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for atrial fibrillation in hypertrophic cardiomyopathy.</article-title>
            <source>Eur J Prev Cardiol</source>
            <year>2021</year>
            <month>May</month>
            <day>22</day>
            <volume>28</volume>
            <issue>6</issue>
            <fpage>658</fpage>
            <page-range>658-665</page-range>
            <pub-id pub-id-type="pmid">30727760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mavrogeni</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Tsarouhas</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Spandidos</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Kanaka-Gantenbein</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bacopoulou</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Sudden cardiac death in football players: Towards a new pre-participation algorithm.</article-title>
            <source>Exp Ther Med</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>1143</fpage>
            <page-range>1143-1148</page-range>
            <pub-id pub-id-type="pmid">30679986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maron</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Myocardial Strain in Hypertrophic&#x000a0;Cardiomyopathy: A Force Worth Pursuing?</article-title>
            <source>JACC Cardiovasc Imaging</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>10</issue>
            <fpage>1943</fpage>
            <page-range>1943-1945</page-range>
            <pub-id pub-id-type="pmid">30660525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rigopoulos</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abate</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Matiakis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Melnyk</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mavrogeni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leftheriotis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bigalke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Noutsias</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Review on sudden death risk reduction after septal reduction therapies in hypertrophic obstructive cardiomyopathy.</article-title>
            <source>Heart Fail Rev</source>
            <year>2019</year>
            <month>May</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>359</fpage>
            <page-range>359-366</page-range>
            <pub-id pub-id-type="pmid">30617667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Authors/Task Force members</collab>
              <name>
                <surname>Elliott</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Anastasakis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Borger</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Borggrefe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cecchi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Charron</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hagege</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Lafont</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Limongelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mahrholdt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McKenna</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Mogensen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nihoyannopoulos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nistri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pieper</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Pieske</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rapezzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rutten</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Tillmanns</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Watkins</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).</article-title>
            <source>Eur Heart J</source>
            <year>2014</year>
            <month>Oct</month>
            <day>14</day>
            <volume>35</volume>
            <issue>39</issue>
            <fpage>2733</fpage>
            <page-range>2733-79</page-range>
            <pub-id pub-id-type="pmid">25173338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maron</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Nishimura</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Spirito</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rakowski</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Towbin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rowin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Maron</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Sherrid</surname>
                <given-names>MV</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Evaluation of Hypertrophic&#x000a0;Cardiomyopathy: JACC State-of-the-Art Review.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2022</year>
            <month>Feb</month>
            <day>01</day>
            <volume>79</volume>
            <issue>4</issue>
            <fpage>372</fpage>
            <page-range>372-389</page-range>
            <pub-id pub-id-type="pmid">35086660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lasala</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rodriguez-Restrepo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Atay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Sepesi</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Systolic anterior motion of the mitral valve-the mechanism of postural hypotension following left intrapericardial pneumonectomy.</article-title>
            <source>J Thorac Dis</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>E354</fpage>
            <page-range>E354-E357</page-range>
            <pub-id pub-id-type="pmid">28523177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marian</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.</article-title>
            <source>Circ Res</source>
            <year>2017</year>
            <month>Sep</month>
            <day>15</day>
            <volume>121</volume>
            <issue>7</issue>
            <fpage>749</fpage>
            <page-range>749-770</page-range>
            <pub-id pub-id-type="pmid">28912181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walsh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mazzarotto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Whiffin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Buchan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Midwinter</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wilk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Felkin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ingold</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Govind</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mazaika</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Allouba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>de Marvao</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ashley</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Colan</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Michels</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Jacoby</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Thomson</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Watkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Barton</surname>
                <given-names>PJR</given-names>
              </name>
              <name>
                <surname>Olivotto</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ware</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy.</article-title>
            <source>Genome Med</source>
            <year>2019</year>
            <month>Jan</month>
            <day>29</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <pub-id pub-id-type="pmid">30696458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Afanasyev</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bogachev-Prokophiev</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lenko</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sharifulin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ovcharov</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kozmin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Karaskov</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Myectomy with mitral valve repair versus replacement in adult patients with hypertrophic obstructive cardiomyopathy: a systematic review and meta-analysis.</article-title>
            <source>Interact Cardiovasc Thorac Surg</source>
            <year>2019</year>
            <month>Mar</month>
            <day>01</day>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>465</fpage>
            <page-range>465-472</page-range>
            <pub-id pub-id-type="pmid">30184144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robyns</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nuyens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Gallacher</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Vandenberk</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Garweg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ector</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pagourelias</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Van Cleemput</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Janssens</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Willems</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Prognostic value of electrocardiographic time intervals and QT rate dependence in hypertrophic cardiomyopathy.</article-title>
            <source>J Electrocardiol</source>
            <year>2018</year>
            <season>Nov-Dec</season>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>1077</fpage>
            <page-range>1077-1083</page-range>
            <pub-id pub-id-type="pmid">30497734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ommen</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Mital</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Evanovich</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Hung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Joglar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kantor</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kimmelstiel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Maron</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Miyake</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Schaff</surname>
                <given-names>HV</given-names>
              </name>
              <name>
                <surname>Semsarian</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sorajja</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2020</year>
            <month>Dec</month>
            <day>22</day>
            <volume>142</volume>
            <issue>25</issue>
            <fpage>e558</fpage>
            <page-range>e558-e631</page-range>
            <pub-id pub-id-type="pmid">33215931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines.</article-title>
            <source>Eur Heart J</source>
            <year>2023</year>
            <month>Dec</month>
            <day>01</day>
            <volume>44</volume>
            <issue>45</issue>
            <fpage>4781</fpage>
            <page-range>4781-4792</page-range>
            <pub-id pub-id-type="pmid">37795986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YJ</given-names>
              </name>
            </person-group>
            <article-title>Performance of 2020 AHA/ACC HCM&#x000a0;Guidelines and Incremental Value of&#x000a0;Myocardial Strain for Predicting SCD.</article-title>
            <source>JACC Asia</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-22</page-range>
            <pub-id pub-id-type="pmid">38222259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markwerth</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bajanowski</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tzimas</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dettmeyer</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Sudden cardiac death-update.</article-title>
            <source>Int J Legal Med</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>135</volume>
            <issue>2</issue>
            <fpage>483</fpage>
            <page-range>483-495</page-range>
            <pub-id pub-id-type="pmid">33349905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Ascenzi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Valentini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pistoresi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Frascaro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Piu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cavigli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Focardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cameli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bonifazi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Metra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mondillo</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Causes of sudden cardiac death in young athletes and non-athletes: systematic review and meta-analysis: Sudden cardiac death in the young.</article-title>
            <source>Trends Cardiovasc Med</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>299</fpage>
            <page-range>299-308</page-range>
            <pub-id pub-id-type="pmid">34166791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ackerman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Triedman</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Sudden Cardiac Death in the Young.</article-title>
            <source>Circulation</source>
            <year>2016</year>
            <month>Mar</month>
            <day>08</day>
            <volume>133</volume>
            <issue>10</issue>
            <fpage>1006</fpage>
            <page-range>1006-26</page-range>
            <pub-id pub-id-type="pmid">26951821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lampert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ackerman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Marino</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Burg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ainsworth</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Salberg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tome Esteban</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Balaji</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barth</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Berul</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Bos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cannom</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Choudhury</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Concannon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Czosek</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Dubin</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Dziura</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eidem</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Emery</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Estes</surname>
                <given-names>NAM</given-names>
              </name>
              <name>
                <surname>Etheridge</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Geske</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Harmon</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Lal</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>McKenna</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Molossi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Olshansky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ommen</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Saarel</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Saberi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Simone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tomaselli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ware</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Zipes</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>SM</given-names>
              </name>
              <collab>LIVE Consortium</collab>
            </person-group>
            <article-title>Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy.</article-title>
            <source>JAMA Cardiol</source>
            <year>2023</year>
            <month>Jun</month>
            <day>01</day>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>595</fpage>
            <page-range>595-605</page-range>
            <pub-id pub-id-type="pmid">37195701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marrakchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kammoun</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bennour</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Laroussi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kachboura</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Risk stratification in hypertrophic cardiomyopathy.</article-title>
            <source>Herz</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <page-range>50-64</page-range>
            <pub-id pub-id-type="pmid">29696341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daubert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gadler</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mabo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Linde</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pacing for hypertrophic obstructive cardiomyopathy: an update and future directions.</article-title>
            <source>Europace</source>
            <year>2018</year>
            <month>Jun</month>
            <day>01</day>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>908</fpage>
            <page-range>908-920</page-range>
            <pub-id pub-id-type="pmid">29106577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maron</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Nishimura</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Spirito</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rakowski</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Towbin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dearani</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rowin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Maron</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Sherrid</surname>
                <given-names>MV</given-names>
              </name>
            </person-group>
            <article-title>Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2022</year>
            <month>Feb</month>
            <day>01</day>
            <volume>79</volume>
            <issue>4</issue>
            <fpage>390</fpage>
            <page-range>390-414</page-range>
            <pub-id pub-id-type="pmid">35086661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ommen</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Mital</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Evanovich</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Hung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Joglar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kantor</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kimmelstiel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Maron</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Miyake</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Schaff</surname>
                <given-names>HV</given-names>
              </name>
              <name>
                <surname>Semsarian</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sorajja</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2020</year>
            <month>Dec</month>
            <day>22</day>
            <volume>76</volume>
            <issue>25</issue>
            <fpage>e159</fpage>
            <page-range>e159-e240</page-range>
            <pub-id pub-id-type="pmid">33229116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Hsi</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zuo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy.</article-title>
            <source>JAMA Cardiol</source>
            <year>2022</year>
            <month>May</month>
            <day>01</day>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>529</fpage>
            <page-range>529-538</page-range>
            <pub-id pub-id-type="pmid">35353129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Batzner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pfeiffer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Neugebauer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aicha</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Blank</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Seggewiss</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2018</year>
            <month>Dec</month>
            <day>18</day>
            <volume>72</volume>
            <issue>24</issue>
            <fpage>3087</fpage>
            <page-range>3087-3094</page-range>
            <pub-id pub-id-type="pmid">30545446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He</surname>
                <given-names>YG</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>HQ</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>YJ</given-names>
              </name>
            </person-group>
            <article-title>Short time effects of two radiofrequency ablation methods on hypertrophic obstructive cardiomyopathy.</article-title>
            <source>Clin Cardiol</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>e24217</fpage>
            <pub-id pub-id-type="pmid">38439605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maron</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Rowin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Maron</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Hypertrophic Cardiomyopathy: New Concepts and Therapies.</article-title>
            <source>Annu Rev Med</source>
            <year>2022</year>
            <month>Jan</month>
            <day>27</day>
            <volume>73</volume>
            <fpage>363</fpage>
            <page-range>363-375</page-range>
            <pub-id pub-id-type="pmid">35084989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tokodi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ol&#x000e1;h</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>F&#x000e1;bi&#x000e1;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lakatos</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Hizoh</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ruppert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sayour</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Barta</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Kiss</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Syd&#x000f3;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Csulak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lad&#x000e1;nyi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Merkely</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kov&#x000e1;cs</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Radovits</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Novel insights into the athlete's heart: is myocardial work the new champion of systolic function?</article-title>
            <source>Eur Heart J Cardiovasc Imaging</source>
            <year>2022</year>
            <month>Jan</month>
            <day>24</day>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>188</fpage>
            <page-range>188-197</page-range>
            <pub-id pub-id-type="pmid">34432004</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18919.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x000fc;bler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Burgstahler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brendel</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gassenmaier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hagen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Klingel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Olthof</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Blume</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wolfarth</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>KAL</given-names>
              </name>
              <name>
                <surname>Greulich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Krumm</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Cardiac MRI findings to differentiate athlete's heart from hypertrophic (HCM), arrhythmogenic right ventricular (ARVC) and dilated (DCM) cardiomyopathy.</article-title>
            <source>Int J Cardiovasc Imaging</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>37</volume>
            <issue>8</issue>
            <fpage>2501</fpage>
            <page-range>2501-2515</page-range>
            <pub-id pub-id-type="pmid">34019206</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
